
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is positioned for substantial long-term growth, evidenced by a 20.6% year-over-year increase in top-line revenue, reaching $252.4 million, which surpassed consensus estimates. The expansion of its product pipeline, including FDA clearance for Type 2 diabetes devices, has more than doubled its addressable market in the U.S., enhancing its growth prospects. Additionally, the company's strong customer satisfaction ratings have resulted in high retention rates and consistent double-digit revenue growth expectations, driven by a combination of pump sales and increasing demand for disposable infusion sets.
Bears say
Tandem Diabetes Care has experienced significant operating losses since its inception and has not demonstrated sustainable profitability, raising concerns about its financial viability. The company provided underwhelming 2025 guidance reflecting weaker-than-expected trends, competition, and potential reimbursement issues, leading to a substantial decline in stock value. Gross margins of 50.7% fell short of consensus estimates, compounding investor apprehension about the company's ability to improve financial performance amidst global economic uncertainties.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares